Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003399 · ClinicalTrials.gov registry record · Phase 2
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003399 is a Phase 2 study that has completed, run by University of Maryland, Baltimore.
The verdict
NCT00003399, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus combination chemotherapy in treating patients who have multiple myeloma.
Interventions
- DRUG cisplatin
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG etoposide
- DRUG carmustine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-09 |
| Est. Completion | 2002-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003399
The ClinicalTrials.gov registry entry for NCT00003399 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00003399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003399 about?
NCT00003399 is a clinical study titled "Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial...
What is the current status of trial NCT00003399?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-09. Estimated completion is 2002-09.
What interventions are being tested in trial NCT00003399?
The interventions under investigation include: cisplatin (DRUG), cyclophosphamide (DRUG), dexamethasone (DRUG), etoposide (DRUG), carmustine (DRUG).
Who is sponsoring clinical trial NCT00003399?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.